Singapore markets closed

22nd Century Group, Inc. (XXII)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2650+0.0050 (+1.92%)
At close: 04:00PM EST
0.2590 -0.01 (-2.26%)
Pre-market: 09:19AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.2600
Open0.2563
Bid0.0000 x 900
Ask0.2679 x 800
Day's range0.2200 - 0.2650
52-week range0.2010 - 18.9750
Volume1,643,418
Avg. volume966,461
Market cap8.34M
Beta (5Y monthly)1.58
PE ratio (TTM)N/A
EPS (TTM)-8.7900
Earnings date06 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est41.11
  • GlobeNewswire

    22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction

    Newly Appointed CEO Leading Restructuring to Focus on Tobacco Industry Operations, Reduce CostsBUFFALO, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the exercise of warrants by certain holders pursuant to its previously announced warrant inducement offering. During the inducement period, certain holders of the Company’s exist

  • GlobeNewswire

    22nd Century Appoints Larry Firestone as Chairman and CEO

    Turnaround Veteran to Focus on Unlocking Shareholder Value in Tobacco AssetsBUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (“22nd Century” or the “Company”), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, “Larry is a seasoned exec

  • GlobeNewswire

    22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise

    Sale Expected to Result in Immediate and Significant Reduction in Operating Costs and Cash RequirementsBUFFALO, N.Y., Nov. 27, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company” or “22nd Century”), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced it has reached an agreement to sell substantially all of its GVB Biopharma (“GVB”) hemp/cannabis operations to Specialty Acquisition Corporation